Antisense oligonucleotides, microRNAs, and antibodies

Area of Science:

• Biochemistry
• Pharmacology
• Genetics

Background:

• Oligonucleotide modifications and Watson-Crick base pairing enable novel drug development.
• Antisense oligonucleotides (ASOs) and miRNA-based therapies target HDL metabolism and function.
• Monoclonal antibodies (mAbs) are emerging as treatments for dyslipidemia and cardiovascular disease.

Purpose of the Study:

• To review recent preclinical and clinical studies on oligonucleotide-based therapies targeting HDL.
• To provide an overview of monoclonal antibodies for dyslipidemia and cardiovascular disease.
• To discuss the potential of these therapies in treating HDL dysfunction and cardiovascular conditions.

Main Methods:

• Review of preclinical and clinical studies on ASOs and miRNA therapies.
• Analysis of clinical trial data for oligonucleotide-based treatments.
• Overview of monoclonal antibody development and clinical testing for dyslipidemia and cardiovascular disease.

Main Results:

• Promising results from recent clinical trials and approvals for oligonucleotide therapies in dyslipidemia.
• ASOs and miRNA therapies show potential for treating HDL dysfunction.
• Monoclonal antibodies are generally safe and well-tolerated in initial studies.

Conclusions:

• Oligonucleotide-based therapies represent unique clinical opportunities for treating HDL dysfunction.
• Despite challenges in mechanism, delivery, specificity, and toxicity, these therapies show significant promise.
• Monoclonal antibodies require further large-scale clinical studies to confirm long-term safety and efficacy.